Total Payments
$702,142
2024 Payments
$65,101
Companies
25
Transactions
535
Medicare Patients
2,741
Medicare Billing
$611,628
Payment Breakdown by Category
Consulting$344,775 (49.1%)
Other$236,468 (33.7%)
Travel$81,876 (11.7%)
Research$25,530 (3.6%)
Food & Beverage$13,469 (1.9%)
Education$25.04 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $344,775 | 95 | 49.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $215,568 | 71 | 30.7% |
| Travel and Lodging | $81,876 | 173 | 11.7% |
| Unspecified | $25,530 | 8 | 3.6% |
| Honoraria | $20,100 | 6 | 2.9% |
| Food and Beverage | $13,469 | 180 | 1.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $800.00 | 1 | 0.1% |
| Education | $25.04 | 1 | 0.0% |
Payments by Type
General
$676,612
527 transactions
Research
$25,530
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $131,537 | 139 | $0 (2019) |
| Amgen Inc. | $110,443 | 64 | $0 (2024) |
| SOBI, INC | $79,779 | 42 | $0 (2024) |
| GENZYME CORPORATION | $62,688 | 38 | $0 (2024) |
| Genentech USA, Inc. | $54,266 | 60 | $0 (2023) |
| SWEDISH ORPHAN BIOVITRUM AB | $43,620 | 6 | $0 (2024) |
| Grifols USA, LLC | $33,245 | 40 | $0 (2023) |
| Dova Pharmaceuticals | $28,745 | 13 | $0 (2021) |
| Novo Nordisk Inc | $24,278 | 17 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $23,195 | 19 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,101 | 23 | SWEDISH ORPHAN BIOVITRUM AB ($29,820) |
| 2023 | $103,031 | 63 | SOBI, INC ($46,342) |
| 2022 | $45,715 | 40 | Sobi, Inc ($28,528) |
| 2021 | $74,694 | 32 | Amgen Inc. ($22,136) |
| 2020 | $82,292 | 42 | Takeda Pharmaceuticals U.S.A., Inc. ($16,481) |
| 2019 | $119,549 | 130 | Shire North American Group Inc ($36,749) |
| 2018 | $88,746 | 95 | Shire North American Group Inc ($46,244) |
| 2017 | $123,015 | 110 | Shire North American Group Inc ($48,545) |
All Payment Transactions
535 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SOBI, INC | DOPTELET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,625.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/08/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $41.96 | General |
| 12/07/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $42.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $78.99 | General |
| 12/05/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $149.71 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/27/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $35.43 | General |
| Category: Hematology | ||||||
| 09/12/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Travel and Lodging | Cash or cash equivalent | $15,020.09 | General |
| 09/12/2024 | SWEDISH ORPHAN BIOVITRUM AB | DOPTELET (Drug) | Consulting Fee | Cash or cash equivalent | $14,800.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/27/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $113.66 | General |
| 07/26/2024 | Amgen Inc. | Nplate (Biological) | Food and Beverage | In-kind items and services | $75.06 | General |
| Category: Hematology | ||||||
| 06/14/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $91.68 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/21/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $14,210.10 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $1,248.75 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $877.50 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $355.35 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $156.93 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $87.41 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $72.46 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $47.90 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | Cash or cash equivalent | $35.90 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $22.56 | General |
| 01/01/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $9,972.00 | General |
| 12/20/2023 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
| 12/11/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $156.49 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Clinical Overview and Practical Considerations for Optimizing Romiplostim Therapy in Patients With | Amgen Inc. | $15,855 | 1 |
| Assessment of Romiplostim Immunogenicity in Pediatric Patients in Clinical Trials and in a Global Postmarketing Registry | Amgen Inc. | $6,281 | 1 |
| Natural History Study of Factor IX Treatment and Complications (B-Natural) | BIOVERATIV THERAPEUTICS INC. | $2,944 | 5 |
| Pediatric ITP Safety Exposure Database | Amgen Inc. | $450.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 852 | 4,293 | $204,619 | $68,796 |
| 2022 | 14 | 734 | 3,561 | $189,641 | $57,712 |
| 2021 | 14 | 631 | 110,619 | $665,456 | $425,920 |
| 2020 | 11 | 524 | 2,925 | $197,550 | $59,199 |
Total Patients
2,741
Total Services
121,398
Medicare Billing
$611,628
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 177 | $50,445 | $16,403 | 32.5% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 80 | 2,018 | $40,360 | $15,998 | 39.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 97 | $22,407 | $7,921 | 35.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 58 | $19,140 | $7,482 | 39.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 42 | 43 | $21,608 | $5,806 | 26.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 187 | 638 | $12,825 | $5,359 | 41.8% |
| 85610 | Blood test, clotting time | Office | 2023 | 64 | 849 | $9,934 | $3,570 | 35.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 132 | 216 | $16,200 | $1,644 | 10.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,778 | $1,464 | 30.7% |
| 85576 | Platelet aggregation function test | Office | 2023 | 16 | 42 | $2,104 | $1,025 | 48.7% |
| 85240 | Clotting factor viii (ahg) measurement | Office | 2023 | 39 | 44 | $1,980 | $771.76 | 39.0% |
| 85246 | Clotting factor viii (vw factor) antigen | Office | 2023 | 17 | 21 | $784.64 | $472.08 | 60.2% |
| 85245 | Clotting factor viii (vw factor) measurement | Office | 2023 | 16 | 20 | $694.00 | $449.60 | 64.8% |
| 85730 | Coagulation assessment blood test, plasma or whole blood | Office | 2023 | 36 | 43 | $918.97 | $253.27 | 27.6% |
| 85335 | Clotting factor inhibitor test | Office | 2023 | 14 | 14 | $441.56 | $176.54 | 40.0% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2022 | 80 | 1,800 | $36,000 | $13,831 | 38.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 45 | 159 | $45,315 | $12,456 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 97 | 105 | $24,255 | $9,104 | 37.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 48 | 49 | $24,623 | $7,520 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 39 | 41 | $13,431 | $4,891 | 36.4% |
| 85610 | Blood test, clotting time | Office | 2022 | 57 | 615 | $7,104 | $2,587 | 36.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $5,513 | $1,833 | 33.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 106 | 202 | $15,150 | $1,540 | 10.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 149 | 469 | $9,400 | $1,387 | 14.8% |
| 99358 | Extended patient service without direct patient contact, first hour | Facility | 2022 | 13 | 14 | $5,880 | $1,198 | 20.4% |
About Dr. Michael Tarantino, MD
Dr. Michael Tarantino, MD is a Pediatric Hematology-Oncology healthcare provider based in Peoria, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1396731063.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Tarantino, MD has received a total of $702,142 in payments from pharmaceutical and medical device companies, with $65,101 received in 2024. These payments were reported across 535 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($344,775).
As a Medicare-enrolled provider, Tarantino has provided services to 2,741 Medicare beneficiaries, totaling 121,398 services with total Medicare billing of $611,628. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Other Specialties Pediatric Hematology-Oncology
- Location Peoria, IL
- Active Since 09/27/2005
- Last Updated 07/30/2021
- Taxonomy Code 2080P0207X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1396731063
Products in Payments
- Nplate (Biological) $103,856
- ADVATE (Biological) $90,513
- Doptelet (Drug) $75,087
- DOPTELET (Drug) $61,945
- HEMLIBRA (Biological) $40,152
- ADYNOVATE (Biological) $22,683
- Thrombate III (Biological) $22,549
- OBIZUR (Biological) $19,892
- Novoeight (Drug) $16,124
- PROMACTA (Drug) $16,076
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) (Biological) $13,832
- BENEFIX (Biological) $11,350
- Alphanate (Biological) $10,846
- ADLYXIN (Biological) $10,338
- Non-Covered Product (Drug) $10,219
- Hemlibra (Biological) $7,998
- Koate (Biological) $3,927
- NO PRODUCT DISCUSSED (Drug) $3,018
- VYVGART (Drug) $1,250
- IXINITY (Drug) $800.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Peoria
Dr. Reuben Antony, Md, MD
Pediatric Hematology-Oncology — Payments: $2,135
Pediatric Hematology-Oncology $2,135
Brinda Mehta, M.d, M.D
Pediatric Hematology-Oncology — Payments: $651.19
Pediatric Hematology-Oncology $651.19
Kay Saving, Md, MD
Pediatric Hematology-Oncology — Payments: $104.52
Pediatric Hematology-Oncology $104.52
Dr. Pedro De Alarcon, Md, MD
Pediatric Hematology-Oncology
Pediatric Hematology-Oncology
Mary Ross, Md, Phd, MD, PHD
Pediatric Hematology-Oncology
Pediatric Hematology-Oncology